Leap Health, a pioneering specialty healthcare platform, has officially announced the launch of a new care model, which is designed to enhance at-home infusion services, as well as unlock transparent, pass-through pricing.
According to certain reports, the stated model makes it possible for employers, benefit managers, and health plans to reduce their costs significantly, while simultaneously elevating patient experience and outcomes.
More on the same would reveal how, with there being no markup on drug prices and clear, fee-for-service billing, Leap Health is able to achieve upto 40% savings per infusion treatment, along with 50% in total cost reductions.
Before we dig any further, we must take into account a fact that, despite US infusion therapy market surging from $150 billion in 2015 to over $360 billion in 2025, an estimated 85% of all infusions continue to occur in hospitals or traditional centers, settings often plagued by high costs, limited flexibility, patient health risks and access challenges.
In case things weren’t bad enough, 2% of employees receiving infusion therapy were found to account for more than half of all specialty drug spending, revealing a massive, often hidden cost driver in employer-sponsored health plans.
Talk about Leap Health’s latest brainchild on a slightly deeper level, we begin from the promise of in-home & center-based infusion therapy. This translates to how patients can receive care in the comfort of their homes or a nearby network partner, something which treads up a long distance to minimize work disruptions, bolster convenience, and at the same time, support stronger treatment adherence.
Next up, we must touch upon the prospect of transparent, pass-through pricing, which effectively eliminates provider markups by basing costs on the true acquisition price of specialty medications. As a result, employers and health plans can come expecting to realize full value from pharmaceutical supply chain efficiencies and removal of buy-and-bill margin.
Another detail worth a mention relates to an aspect focused on flexible, employee-centric scheduling. You see, appointments are aligned with employees’ availability so to reduce time off work and increase treatment accessibility.
Then, there is the prospect of a superior patient experience. With 98% of patients reporting higher satisfaction, home infusions have already showcased indications for better adherence and improved health outcomes.
Joining that would be the availability of end-to-end clinical support. The stated support stems from how Leap coordinates the entire infusion journey, including clinical oversight, drug procurement, scheduling, and personalized management.
Hold on, we still have a few bits left to unpack, considering we haven’t yet touched upon Leap Health’s bid to achieve site-of-care optimization, as redirecting treatments away from high-cost hospital settings has already delivered $500,000+ in savings for some individual high-cost patients.
We also haven’t touched upon the model’s pledge to cut down on specialty drug costs. In essence, Leap drives an average of $5m savings per 10,000 eligible members for large employers.
Rounding up highlights would be a factor which claims that Leap’s nurse network covers 100% of current claim zip codes, ensuring accessibility and continuity of care for employees wherever they are.
“Infusion therapy is one of the most opaque and costly aspects of modern healthcare,” said Rob LaHayne, CEO of Leap Health. “We built Leap to shine a light on this hidden cost driver and to offer employers and patients a smarter, more humane alternative. Through site-of-care optimization and direct pricing transparency, we’re transforming the way infusion therapy is delivered and experienced.”
